Filter Results
:
(172)
Show Results For
-
All HBS Web
(629)
- Faculty Publications (172)
Show Results For
-
All HBS Web
(629)
- Faculty Publications (172)
- March 2008 (Revised January 2023)
- Supplement
Cadbury Schweppes: Capturing Confectionery (B)
By: David Collis, Toby Stuart and Troy Smith
In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a...
View Details
Collis, David, Toby Stuart, and Troy Smith. "Cadbury Schweppes: Capturing Confectionery (B)." Harvard Business School Supplement 708-454, March 2008. (Revised January 2023.)
- March 2008 (Revised July 2011)
- Supplement
Cadbury Schweppes: Capturing Confectionery (C)
By: David Collis, Toby Stuart and Troy Smith
In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a...
View Details
Collis, David, Toby Stuart, and Troy Smith. "Cadbury Schweppes: Capturing Confectionery (C)." Harvard Business School Supplement 708-455, March 2008. (Revised July 2011.)
- March 2008 (Revised July 2011)
- Supplement
Cadbury Schweppes: Capturing Confectionery (D)
By: David Collis, Toby Stuart and Troy Smith
In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a...
View Details
Collis, David, Toby Stuart, and Troy Smith. "Cadbury Schweppes: Capturing Confectionery (D)." Harvard Business School Supplement 708-491, March 2008. (Revised July 2011.)
- March 2008
- Case
Novartis AG: Science-Based Business
By: H. Kent Bowen and Courtney Purrington
Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,...
View Details
Keywords:
Innovation and Invention;
Resource Allocation;
Product Development;
Partners and Partnerships;
Research and Development;
Science-Based Business;
Pharmaceutical Industry
Bowen, H. Kent, and Courtney Purrington. "Novartis AG: Science-Based Business." Harvard Business School Case 608-136, March 2008.
- November 2007
- Case
Antegren: A Beacon of Hope
By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann
The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion...
View Details
Keywords:
Demand and Consumers;
Leadership;
Ethics;
Corporate Social Responsibility and Impact;
Decision Choices and Conditions;
Crisis Management;
Health Testing and Trials;
Pharmaceutical Industry;
Pharmaceutical Industry
Margolis, Joshua D., Thomas J. DeLong, and Terence Heymann. "Antegren: A Beacon of Hope." Harvard Business School Case 408-025, November 2007.
- November 2007
- Supplement
Teva Pharmaceutical Industries, Ltd.
By: Tarun Khanna and Krishna G. Palepu
How do companies develop a strategy that is both low-cost and differentiated without becoming squeezed in the middle? Describes how Teva, Israel's largest and first multinational, achieved its globally dominant position in generic pharmaceuticals, an industry that has...
View Details
Keywords:
Multinational Firms and Management;
Emerging Markets;
Rank and Position;
Competitive Strategy;
Pharmaceutical Industry;
Israel;
India
Khanna, Tarun, and Krishna G. Palepu. "Teva Pharmaceutical Industries, Ltd." Harvard Business School Video Supplement 708-806, November 2007.
- September 2007 (Revised December 2008)
- Case
Michael Fernandes at Nicholas Piramal
By: Michel Anteby and Nitin Nohria
Michael Fernandes, the Director of Custom Manufacturing Operations at the pharmaceutical company Nicholas Piramal India Limited (NPIL), schedules a meeting with three of his reports, whose interpersonal conflicts with one another are causing his business development...
View Details
Keywords:
Interpersonal Communication;
Management Skills;
Groups and Teams;
Conflict Management;
Cooperation;
Pharmaceutical Industry;
India;
United Kingdom;
Canada
Anteby, Michel, and Nitin Nohria. "Michael Fernandes at Nicholas Piramal." Harvard Business School Case 408-001, September 2007. (Revised December 2008.)
- September 2007
- Article
Investigative Negotiation
By: Deepak Malhotra and Max H. Bazerman
This article includes a one-page preview that quickly summarizes the key ideas and provides an overview of how the concepts work in practice along with suggestions for further reading. Negotiators often fail to achieve results because they channel too much effort into...
View Details
Keywords:
Knowledge Acquisition;
Knowledge Use and Leverage;
Negotiation Process;
Negotiation Tactics;
Motivation and Incentives;
Perspective;
Pharmaceutical Industry
Malhotra, Deepak, and Max H. Bazerman. "Investigative Negotiation." Harvard Business Review 85, no. 9 (September 2007).
- May 2007 (Revised September 2008)
- Case
Biocon Limited
By: Krishna G. Palepu and Ananth Chepuri
Biocon Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an innovation-led strategy. This new...
View Details
Keywords:
Globalized Firms and Management;
Innovation and Management;
Leading Change;
Growth and Development Strategy;
Risk Management;
Organizational Change and Adaptation;
Biotechnology Industry;
India
Palepu, Krishna G., and Ananth Chepuri. "Biocon Limited." Harvard Business School Case 107-083, May 2007. (Revised September 2008.)
- November 2006 (Revised July 2008)
- Case
Eli Lilly: Developing Cymbalta
By: Elie Ofek and Ron Laufer
Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug. In particular, the company needs to decide whether to first establish that once-a-day dosing for Cymbalta...
View Details
Keywords:
Decision Choices and Conditions;
Marketing Strategy;
Product Launch;
Product Development;
Research and Development;
Pharmaceutical Industry
Ofek, Elie, and Ron Laufer. "Eli Lilly: Developing Cymbalta." Harvard Business School Case 507-044, November 2006. (Revised July 2008.)
- September 2006 (Revised March 2010)
- Case
Teva Pharmaceutical Industries, Ltd
By: Tarun Khanna, Krishna G. Palepu and Claudine Deborah Madras
How do companies develop a strategy that is both low-cost and differentiated without becoming squeezed in the middle? Describes how Teva, Israel's first and largest multinational, achieved its globally dominant position in generic pharmaceuticals, an industry that has...
View Details
Keywords:
Multinational Firms and Management;
Emerging Markets;
Rank and Position;
Competitive Strategy;
Pharmaceutical Industry;
India;
Israel
Khanna, Tarun, Krishna G. Palepu, and Claudine Deborah Madras. "Teva Pharmaceutical Industries, Ltd." Harvard Business School Case 707-441, September 2006. (Revised March 2010.)
- January 2006 (Revised July 2006)
- Case
Drug Testing in Nigeria (A)
By: Debora L. Spar
In 1996, a meningitis epidemic swept across Nigeria. Thousands of children were struck and, lacking appropriate medicine, were liable to die from the disease. Doctors at Pfizer had an antibiotic that could probably save most of these children's lives. The drug was new,...
View Details
Keywords:
Risk and Uncertainty;
Health Pandemics;
Health Testing and Trials;
Developing Countries and Economies;
Pharmaceutical Industry;
Nigeria
Spar, Debora L., and Adam Day. "Drug Testing in Nigeria (A)." Harvard Business School Case 706-033, January 2006. (Revised July 2006.)
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and...
View Details
Keywords:
Health Care and Treatment;
Strategic Planning;
Competition;
Patents;
Innovation and Invention;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- September 2005 (Revised June 2006)
- Case
WuXi PharmaTech
By: Richard G. Hamermesh and Simin Zhou
WuXi Pharmatech has gone from zero to $21 million in sales in three years. The company must decide its growth strategy and how best to finance and organize for rapid growth.
View Details
Keywords:
Growth Management;
Capital Markets;
Problems and Challenges;
Pharmaceutical Industry;
China
Hamermesh, Richard G., and Simin Zhou. "WuXi PharmaTech." Harvard Business School Case 806-003, September 2005. (Revised June 2006.)
- February 2005 (Revised April 2006)
- Case
Rx Depot: Importing Drugs from Canada
By: Debora L. Spar
In 2002, a handful of entrepreneurs began to ship drugs from Canada into the United States, taking advantage of regulatory and price differentials across the neighboring countries. Using the Internet and a low-cost network of Canadian pharmacies, firms like Rx Depot...
View Details
Keywords:
Courts and Trials;
Entrepreneurship;
Intellectual Property;
Laws and Statutes;
Pharmaceutical Industry;
Canada;
United States
Spar, Debora L., and Adam Day. "Rx Depot: Importing Drugs from Canada." Harvard Business School Case 705-010, February 2005. (Revised April 2006.)
- January 2005 (Revised March 2006)
- Case
Molecular Insight Pharmaceuticals, Inc.
By: Richard G. Hamermesh and Edwin W. Parkinson III
Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing....
View Details
Keywords:
Intellectual Property;
Health Care and Treatment;
Pharmaceutical Industry;
Pharmaceutical Industry
Hamermesh, Richard G., and Edwin W. Parkinson III. "Molecular Insight Pharmaceuticals, Inc." Harvard Business School Case 805-067, January 2005. (Revised March 2006.)
- July 2004 (Revised May 2005)
- Case
Pfizer's Virtual CIO (Abridged)
By: F. Warren McFarlan and Brian DeLacey
Discusses the IT organization and IT strategy issues facing Pfizer, one of the world's largest pharmaceutical companies. Managing over $1 billion of IT expense, the company has a committee approach for handling all critical IT decisions, an approach that is consistent...
View Details
Keywords:
Decision Making;
Cost Management;
Organizational Culture;
Strategy;
Information Technology;
Pharmaceutical Industry
McFarlan, F. Warren, and Brian DeLacey. "Pfizer's Virtual CIO (Abridged)." Harvard Business School Case 305-018, July 2004. (Revised May 2005.)
- June 2004
- Case
Aventis SA (A): Planning for a Merger
By: Joshua D. Margolis and Carin-Isabel Knoop
Eight executives at Hoechst and Rhone-Poulenc must make four crucial decisions on the eve of merging their companies to become Aventis--what would become the world's third largest pharmaceutical firm. In addition to formulating a vision and strategy, the two firms must...
View Details
Keywords:
Problems and Challenges;
Mergers and Acquisitions;
Horizontal Integration;
Organizational Design;
Organizational Culture;
Pharmaceutical Industry;
United States
Margolis, Joshua D., and Carin-Isabel Knoop. "Aventis SA (A): Planning for a Merger." Harvard Business School Case 404-003, June 2004.
- June 2004
- Case
Aventis SA (B): A Company is Born
By: Joshua D. Margolis and Carin-Isabel Knoop
Supplements the (A) case.
View Details
Keywords:
Problems and Challenges;
Mergers and Acquisitions;
Horizontal Integration;
Organizational Design;
Organizational Culture;
Pharmaceutical Industry;
United States
Margolis, Joshua D., and Carin-Isabel Knoop. "Aventis SA (B): A Company is Born." Harvard Business School Case 404-108, June 2004.
- June 2004 (Revised June 2006)
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (A)
By: Gary P. Pisano, Lee Fleming and Eli Strick
Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will...
View Details
Pisano, Gary P., Lee Fleming, and Eli Strick. "Vertex Pharmaceuticals: R&D Portfolio Management (A)." Harvard Business School Supplement 604-101, June 2004. (Revised June 2006.)